ReviewFrontiers in cellular and infection microbiology2025
Immunometabolic reprogramming in diabetic osteomyelitis: from mechanisms to therapeutics.
Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bone‑origin repair in diabetic foot ulcers: Mechanisms of callus formation and endocrine effects in healing (Review).International journal of molecular medicine · 2026Review
- Metformin as a Metabolic Reprogramming Interface in Host-Pathogen and Bone Microenvironment Crosstalk: A Dual-Target Strategy Against Antimicrobial Resistance and Osteoporotic Bone Loss.Antibiotics (Basel, Switzerland) · 2026Review
- Fueling bone loss: the immunometabolic reprogramming of the bone microenvironment in diabetic osteoporosis.Frontiers in immunology · 2026Review
- Clinicopathological and microbiological profile of osteomyelitis at a teaching hospital in India: A retrospective study.Bioinformation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a globally prevalent metabolic disorder characterized by impaired immune function due to poor glycaemia control, significantly increasing the risk of osteomyelitis. The occurrence of bone infection not only compromises patients' quality of life but also poses substantial challenges in clinical management. Recent studies have identified immunometabolic reprogramming as a pivotal player in the pathogenesis and progression of diabetic osteomyelitis. This reprogramming not only disrupts immune cell functionality but also modulates the local microenvironment, thereby impairing bone repair processes. Although preliminary research has explored the underlying mechanisms, a comprehensive understanding of the precise role of immunometabolic reprogramming and its potential therapeutic targeting in diabetic osteomyelitis remains elusive. This review synthesizes current advances in immunometabolic reprogramming within diabetic osteomyelitis, elucidates its biological mechanisms, and proposes novel intervention strategies to inform clinical practice and inspire future therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.